TuHURA Biosciences Initiates Phase 3 Trial and Plans Kineta Acquisition Amid Strong Q1 2025 Results
TuHURA Biosciences, Inc. reported strong first quarter 2025 financial results and provided updates on its Phase 3 immune-oncology trials and acquisition plans.
2 minutes to read